Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
xNTPDdM9M7RbF3KD
Listen
